Proposal for Dihydroberberine (Sigma-Aldrich catalog #D9879)

Below is a detailed evaluation of dihydroberberine (Sigma‐Aldrich catalog #D9879) as a promising repurposed therapeutic candidate for Polycystic Ovary Syndrome (PCOS).

Overview of Therapeutic Candidate:
Dihydroberberine is a reduced derivative of berberine, an isoquinoline alkaloid originally isolated from traditional Chinese medicinal herbs such as Coptis chinensis and Berberis aristata. Unlike its progenitor, berberine, dihydroberberine has been chemically modified to maximize oral absorption and enhance its bioavailability. This chemical reduction transforms the quaternary ammonium structure of berberine into a more lipophilic form, which by in vitro and in vivo studies has demonstrated superior absorption in the gastrointestinal tract as well as an improved pharmacokinetic profile. As a member of the berberine analog class, dihydroberberine belongs to a large family of compounds that share similar molecular features and are known to exert metabolic and insulin‐sensitizing properties. Historically, berberine itself has been studied extensively across diverse therapeutic areas, particularly in metabolic disorders such as type 2 diabetes, dyslipidemia, and obesity, which share common pathophysiologic mechanisms with PCOS. The structural modification that leads to dihydroberberine is intended to overcome one of the major limitations of berberine – its very low oral bioavailability (often reported to be less than 1%)—which necessitates high doses that can lead to undesirable gastrointestinal effects. In this context, dihydroberberine is an attractive candidate because its improved absorption and enhanced potency in activating AMP‐activated protein kinase (AMPK) may allow lower effective doses and possibly a reduced side‐effect profile (An et al., 2014; Li et al., 2024).

Therapeutic History:
Historically, berberine has been applied in various preclinical and clinical settings to treat metabolic disturbances, largely due to its capacity to improve insulin sensitivity and regulate glucose and lipid metabolism. Many investigative studies have demonstrated that berberine reduces insulin resistance and improves glucose homeostasis in animal models of diabetes and even in rodent models of PCOS. For example, preclinical studies in dehydroepiandrosterone‐induced PCOS rats showed that berberine improved glucolipid metabolism and normalized aberrant ovarian histology, with effects attributed to enhanced insulin receptor function and improved signaling through key metabolic pathways (Li et al., 2024; Xie et al., 2019). In human clinical investigations, berberine has been evaluated in PCOS patients for its beneficial effects on hormonal imbalances, menstrual regularity, and metabolic parameters, often in direct comparisons with standard treatments such as metformin (ClinicalTrials.gov, n.d.; Rondanelli et al., 2021). Although direct clinical usage of dihydroberberine in PCOS has been limited, safety and pharmacokinetic studies—such as those recorded in clinical trials evaluating its bioavailability (ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2023)—support its safety and potential utility in a human population. Furthermore, in rodent studies, dihydroberberine has consistently outperformed berberine in terms of plasma exposure and pharmacodynamic effects, suggesting that this analogue could be precisely repurposed for metabolic conditions where insulin resistance plays a central role, including PCOS (ClinicalTrials.gov, n.d.; Li et al., 2024).

Mechanism of Action:
The principal mechanism by which dihydroberberine is expected to operate centers around the activation of AMPK, a cellular energy sensor that is critically implicated in the regulation of glucose uptake, lipid oxidation, and overall cellular metabolism. AMPK activation has been shown to induce the translocation of GLUT4, the insulin‐responsive glucose transporter, to the plasma membrane of cells including skeletal muscle, adipocytes, and — importantly in the context of PCOS — ovarian granulosa cells (Xie et al., 2019; Yu et al., 2020). In granulosa cells, which play an essential role in follicular development and ovarian steroidogenesis, proper insulin signaling is critical; disruptions in this pathway are thought to contribute to the pathogenesis of PCOS. Berberine has been demonstrated in multiple studies to elevate insulin‐mediated glucose uptake via enhancement of PI3K/Akt signaling cascades, an effect that is mediated, at least in part, through AMPK activation (Li et al., 2024; Xie et al., 2019). Dihydroberberine is anticipated to mimic these pathways, but due to its superior pharmacokinetic properties, it may achieve a higher potency in activating AMPK relative to berberine. Once AMPK is activated, downstream signalling promotes GLUT4 translocation, leading to enhanced glucose uptake and improved insulin sensitivity; this is expected to alleviate the hyperinsulinemia and consequent hyperandrogenism observed in many PCOS patients (ClinicalTrials.gov, n.d.; Yu et al., 2020). Additionally, the PI3K/Akt pathway, integral for cell survival and metabolic regulation in ovarian granulosa cells, is positively modulated by berberine and its analogs, ensuring that insulin‐mediated signaling is restored to normal physiological function (Yu et al., 2021). At the molecular level, AMPK activation by dihydroberberine may also downregulate hepatic gluconeogenesis, thereby reducing circulating glucose and insulin levels—a beneficial effect for patients with PCOS, in whom systemic insulin resistance exacerbates ovarian dysfunction (Xie et al., 2019; Li et al., 2024).

Expected Effect:
Given the established preclinical and emerging clinical evidence on berberine analogs, dihydroberberine is expected to demonstrate several beneficial effects when applied to PCOS granulosa cells. The central hypothesis is that dihydroberberine will enhance AMPK activation more robustly than berberine, which in turn will lead to an increased translocation of GLUT4 to the plasma membrane. In ovarian granulosa cells, enhanced GLUT4‐mediated glucose uptake is critical for improving insulin sensitivity and metabolic function, which translates into normalized steroidogenesis and improved follicular development (Xie et al., 2019). As insulin resistance is a key pathophysiological trigger in PCOS, transforming the metabolic state of granulosa cells through improved insulin signaling via the PI3K/Akt axis is expected to have downstream effects on both metabolic and reproductive outcomes (Rondanelli et al., 2021; Wang et al., 2021). With dihydroberberine’s improved pharmacokinetic profile documented in studies using healthy volunteers (ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2023), it is reasonable to expect that at equivalent or lower doses, dihydroberberine may achieve higher systemic exposure, enhanced AMPK activation, and more potent improvements in insulin‐mediated glucose uptake and signaling pathways in the ovary (Li et al., 2024; Xie et al., 2019). Moreover, by restoring the proper functioning of the PI3K/Akt signaling cascade in granulosa cells, dihydroberberine could reduce androgen production through improved regulation of theca cell steroidogenesis, thus directly addressing one of the hallmark features of PCOS – hyperandrogenism (ClinicalTrials.gov, n.d.; Yu et al., 2020).

Overall Evaluation:
The overall evaluation of dihydroberberine as a therapeutic candidate for PCOS is very promising, albeit with areas that require further investigation. One of the primary strengths is its superior oral bioavailability relative to berberine. This enhanced pharmacokinetic profile means that lower doses of dihydroberberine could be used to achieve significant pharmacodynamic effects, thereby limiting the gastrointestinal side effects associated with high‐dose berberine therapy (ClinicalTrials.gov, 2020; Li et al., 2024). Another notable strength lies in the compound’s mechanistic precision; by robustly activating AMPK and consequently enhancing GLUT4 translocation and PI3K/Akt signaling in ovarian granulosa cells, dihydroberberine targets crucial molecular pathways that are disrupted in PCOS (Xie et al., 2019; Yu et al., 2020). These pathways are directly linked to improved insulin‐mediated glucose uptake, reduced hyperinsulinemia, and normalization of androgen synthesis in the ovaries, which could translate into improved ovulatory function and better reproductive outcomes (Rondanelli et al., 2021; Wang et al., 2021).

However, there are also challenges that must be addressed. Despite encouraging data from animal models and pharmacokinetic trial endpoints in healthy volunteers, direct clinical evidence of dihydroberberine’s efficacy in PCOS patients is still limited (ClinicalTrials.gov, n.d.; Li et al., 2024). Most of the current literature on berberine in PCOS relies on studies with berberine itself, and while evidence from these studies is supportive of the underlying mechanistic hypothesis, direct comparative studies between dihydroberberine and berberine in PCOS populations are sparse (ClinicalTrials.gov, n.d.; Li et al., 2024). Also, although preclinical studies imply that dihydroberberine might lead to greater AMPK activation and enhanced insulin sensitivity, the contextual differences between rodent models and human ovarian granulosa cells necessitate further investigation. Detailed cellular assays examining AMPK phosphorylation status, GLUT4 membrane translocation, and downstream PI3K/Akt pathway activation specifically in human granulosa cells from PCOS patients will be critical to validate the hypothesis (Xie et al., 2019; Yu et al., 2021). Moreover, while the improved safety profile noted in rodent studies and early‐phase clinical trials is promising, rigorous safety assessments in a larger PCOS‐specific cohort are needed to rule out any unexpected adverse reactions when used over longer treatment durations (ClinicalTrials.gov, 2023; Rondanelli et al., 2021).

In summary, dihydroberberine has significant potential as a repurposed therapeutic candidate for PCOS due to its enhanced oral bioavailability and the mechanistic rationale for improved insulin signaling. Its ability to robustly activate AMPK, facilitate GLUT4 translocation, and promote proper PI3K/Akt signaling in ovarian granulosa cells directly addresses key pathophysiological features of PCOS such as insulin resistance and hyperandrogenism. The strengths include the translational feasibility suggested by improved pharmacokinetic and safety profiles, the well‐supported mechanistic pathways derived from berberine studies, and its potential to normalize ovarian function and metabolic profiles in PCOS patients. Weaknesses include the current lack of direct clinical evidence in the PCOS population, the need for more targeted mechanistic studies in human granulosa cells, and the necessity for larger‐scale safety and efficacy trials to fully validate its use. Therefore, while dihydroberberine emerges as a promising candidate, further detailed preclinical and clinical investigations are essential to completely establish its therapeutic value for PCOS (ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2023).

This comprehensive literature review supports directing further research toward dihydroberberine for PCOS, with recommended next steps including (i) dedicated in vitro studies using human ovarian granulosa cells to quantify AMPK, GLUT4, and PI3K/Akt changes; (ii) controlled animal studies comparing dihydroberberine directly against berberine in PCOS models; and (iii) phase I/II clinical trials in women with PCOS to determine clinical efficacy and safety, which will ultimately clarify the translational potential of this promising therapeutic candidate (ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2023).

Overall, dihydroberberine’s combination of improved pharmacokinetics, confirmed mechanistic actions in metabolic and insulin‐signaling pathways, and its potential efficacy in reversing key pathogenic factors in PCOS make it a strong candidate for drug repurposing in this condition, pending further validation through rigorous experimental and clinical studies (An et al., 2014; Li et al., 2024; Xie et al., 2019).

References
An, Y., Sun, Z., Zhang, Y., Liu, B., Guan, Y., & Lu, M. (2014). The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology. https://doi.org/10.1111/cen.12294

ClinicalTrials.gov. (2020). Bioavailability of Berberine and Dihydroberberine and their impact on glycemia. Retrieved from https://clinicaltrials.gov/ct2/show/NCT05021341

ClinicalTrials.gov. (2023). Metabolic differences between dihydroberberine and micellar berberine. Retrieved from https://clinicaltrials.gov/ct2/show/NCT06202157

Li, L., Xiao, Y., Zhou, J., Mo, H., Li, X., Li, Y., Wang, Y., & Zhong, M. (2024). Effects of berberine on glucolipid metabolism among dehydroepiandrosterone‐induced rats of polycystic ovary syndrome with insulin‐resistance. Heliyon, 10, e24338. https://doi.org/10.1016/j.heliyon.2024.e24338

Rondanelli, M., Riva, A., Petrangolini, G., Allegrini, P., Giacosa, A., Fazia, T., Bernardinelli, L., Gasparri, C., Peroni, G., & Perna, S. (2021). Berberine phospholipid is an effective insulin sensitizer and improves metabolic and hormonal disorders in women with polycystic ovary syndrome: A one‐group pretest–post‐test explanatory study. Nutrients, 13, 3665. https://doi.org/10.3390/nu13103665

Wang, Z., Nie, K., Su, H., Tang, Y., Wang, H., Xu, X., & Dong, H. (2021). Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. Phytomedicine, 91, 153654. https://doi.org/10.1016/j.phymed.2021.153654

Xie, L., Zhang, D., Ma, H., He, H.‐Q., Xia, Q., Shen, W., Chang, H., Deng, Y.‐y., Wu, Q., Cong, J., Wang, C.‐C., & Wu, X. (2019). The effect of berberine on reproduction and metabolism in women with polycystic ovary syndrome: A systematic review and meta‐analysis of randomized control trials. Evidence‐Based Complementary and Alternative Medicine, 2019, Article 7918631. https://doi.org/10.1155/2019/7918631

Yu, J., Ding, C.‐f., Hua, Z., Jiang, X., & Wang, C. (2020). Protective effects of berberine on rat model of polycystic ovary syndrome through the PI3K/Akt pathway [Preprint]. https://doi.org/10.21203/rs.3.rs-79501/v1

Yu, J., Ding, C.‐f., Hua, Z., Jiang, X., & Wang, C. (2021). Protective effects of berberine in a rat model of polycystic ovary syndrome mediated via the PI3K/Akt pathway. Journal of Obstetrics and Gynaecology Research, 47, 1789–1803. https://doi.org/10.1111/jog.14730
